Primel, a leading provider of innovative infection prevention infrastructure, has announced the results from a first-of-its-kind clinical trial at Lancashire Teaching Hospital Trust of its Primel Active Hand Shield (PAHS) technology. In the trial, PAHS demonstrated an average of 91% higher antimicrobial efficacy after 1 hour, compared to the current standard of care hand sanitizer at 15 minutes. This is the world’s first-hand hygiene product that has both a broad spectrum of antimicrobial activity and long lasting (residual) efficacy, so providing much improved protection for patients. Use of this innovative product will improve patient safety, addressing the current challenges of hand hygiene compliance by healthcare workers, and reduce the cost and burden of healthcare associated infections. These unrivalled efficacy results that include the first broad spectrum efficacy with sustained protection, that is effective against pathogens such as MRSA, Clostridium difficile and norovirus. This highlights the evolution of Primel’s infection prevention solution and provides an opportunity to review national and international health policies for safer hand hygiene.